|Last Price$11.12||Day Change (%)11.76%|
|Open Price$10.01||Day Change ($)1.17|
|Day Range9.86–11.16||52-Week Range5.90–13.18|
As of Fri 7/29/2016 5:00:00 PM | USD
Cytokinetics' CYTK ispinesib trial results for head and neck cancer did not yield a statistically significant change in its patients. We are leaving our fair value estimate at $3.50 per share, as we had already assigned a low probability of success for this indication. Our more conservative ...
Cytokinetics faces challenging odds.